Press Releases

Date Title
2/27/19 Sarepta Exercises Option to Acquire Myonexus Therapeutics
2/20/19 Sarepta Therapeutics to Announce Limb-Girdle Muscular Dystrophy Type 2E Data Results and Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Developments on February 27, 2019
2/14/19 Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)
2/14/19 Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
1/31/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/2/19 Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy
1/2/19 Sarepta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
12/31/18 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/20/18 Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
12/11/18 Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
Displaying 71 - 80 of 635